The company will present preclinical data on the otoprotective capacity of SENS-401 which may benefit cochlear implant patients
MONTPELLIER, France, June 06, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, will present at the International Conference on Cochlear Implants and Other Implantable Auditory Technologies (Ci2018), at the Flanders Meeting & Convention Center Antwerp, Belgium from June 27th to 30th, 2018.
Sensorion will present preclinical data on SENS-401’s potential to prevent sensory hair cell damage. This could improve the hearing loss outcomes for patients undergoing cochlear implant surgery.
The details of the oral presentation are as follows:
| Session: | Next-Generation Electrodes: Pharmacological Structure Preservation | |
| Abstract Title: | Potential for Pharmacological Protection Against Loss of Residual Hearing After Cochlear Implant Surgery Using the Clinical-Stage Oral Otoprotectant SENS-401 | |
| Date & Time: | Thursday, June 28th from 2:40 PM – 3:30 PM CEST | |
| Location: | Gorilla 3 Room |
About Ci2018
The International Conferences on Cochlear Implants and other Implantable Auditory Technologies are the most comprehensive, innovative and inclusive events of their kind with more than 2000 otologists, audiologists and speech pathologists, scientists, educators and industrial partners. This 15th edition of the conference aims to realize a next step forwards in the field, based on evidence based experience and fueled by cutting-edge technologies and the latest scientific developments.
About SENS-401
SENS-401, R-azasetron besylate, is a drug candidate that aims to protect and preserve inner ear tissue when lesions are present that can cause progressive or sequelae hearing impediments. A small molecule that can be taken orally or via an injection, SENS-401 has received Orphan Drug Designation in Europe for the treatment of sudden sensorineural hearing loss, and Orphan Drug Designation from the US FDA for the prevention of platinum-induced ototoxicity in pediatric population.
About Sensorion
Sensorion is a biotech company pioneering novel treatments of inner ear diseases such as severe vertigo, tinnitus or hearing loss. Two products are currently in the clinical development stage: SENS-111, in phase 2 in acute unilateral vestibulopathy (vestibular neuritis), and SENS-401, which has completed a phase 1 trial. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drugs for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus.
Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.
Sensorion has been listed on the Euronext Growth Paris exchange since April 2015.
www.sensorion-pharma.com
| Contacts | |
| Sensorion Nawal Ouzren CEO contact@sensorion-pharma.com Tél : +33(0) 467 207 730 | Investor Relations LifeSci Advisors LLC Chris Maggos chris@lifesciadvisors.com Tél. : +41 79 367 6254 |
| Label : SENSORION ISIN : FR0012596468 Mnemonic : ALSEN | Press Alize RP Caroline Carmagnol & Wendy Rigal sensorion@alizerp.com |
Disclaimer
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence registration document filed with the Autorité des marchés financiers (AMF- French Financial Market Authority) on July 28, 2016 under n°R.16-069 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.